Publication | Closed Access

Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement

OncologyC-met AmplificationOncogenic AgentMedicineAlk RearrangementPathologyBronchial NeoplasmCancer TreatmentPharmacologyDual Met/alk InhibitorLung Cancer